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Abstract: Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their
use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the
biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has
renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry
community to develop novel and selective human DHFR inhibitors, thus leading to a new generation
of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile
of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery
are also provided, in order to thoroughly delineate the current landscape for medicinal chemists
interested in furthering this study in the anticancer field.
Keywords: dihydrofolate reductase (DHFR) enzyme; DHFR inhibitors as anticancer agents;
heterocyclic compounds; DHFR drug discovery; hybrid compounds
1. Introduction
Since the middle of the last century, the potential of the dihydrofolate reductase (DHFR) enzyme
as a therapeutic target for treating infections has been evidenced [1,2]. DHFR catalyzes the reduction
of dihydrofolate to tetrahydrofolate using NADPH, and it is involved in the synthesis of raw material
for cell proliferation, in both prokaryotic and eukaryotic cells. DHFR inhibitors are commonly
used for fighting malaria and other protozoal infections, as well as for treating fungal, bacterial,
and mycobacterial infections [3]. Over the years, several compounds have been discovered and
different drugs have entered the market. Among them, we have to mention pyrimethamine and
proguanil as antimalarial drugs [4,5]; trimethoprim, an antibacterial drug commonly used in association
with sulfonamides, like sulfamethoxazole [6,7]; and methotrexate, the first-in-class anti-cancer agent
acting via DHFR inhibition [8,9]. Methotrexate inhibits DHFR with a high affinity, thus reducing
the amount of tetrahydrofolates required for the synthesis of pyrimidine and purines. Consequently,
RNA and DNA synthesis is stopped and the cancer cells die. From a chemical standpoint, methotrexate
shows several drawbacks, such as a poor solubility and relevant toxic side effects [10–12]. DHFR
inhibitors are among the most used classes of anticancer agents and finding novel agents with a
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promising pharmacological profile still remains one of the major challenges for medicinal chemists,
as testified by the literature trend of the last 20 years.
In this review, after a brief overview of the physiological role of DHFR in cells and particularly in
cancer cells, we focus on DHFR inhibitors for cancer therapy. Particularly, we highlight compounds
already marketed and new scaffolds that could be relevant for anticancer therapy.
2. Physiological Role and Structure of DHFR
Folic acid (FA) is a water-soluble vitamin important for biological systems. It is not biologically
active per se, but it is the precursor of the active form known as tetrahydrofolate (THF), which is
essential for the de novo synthesis of purines, amino acids, and thymidylate (TMP) [13]. It has been
demonstrated that its absence causes the inhibition of cell growth and proliferation [14]. The synthetic
pathway that allows the transformation of FA in THF is reported in Figure 1.
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has collected over one hun red structures obtained from both eukaryotic and prokaryotic organisms
(humans, Escherichia coli, Lactobacillus casei, Pneumocystis carinii, Micobacterium tuberculosis, etc.), alone or
in complex with different ligands [16]. Briefly, DHFR consists of eight sheets, which form a rigid
skeleton: seven sheets run parallel and the other runs antiparallel. All the enzyme isoforms contain
at least four α-helices intersecting in the long loops of the sheets. Furthermore, one loop forms the
binding site for the substrate, while another two form the binding site of the coenzyme NADPH. It is
interesting to note that DHFR has no disulfide bridges and it does not need to be coordinated by
metal ions to exercise its biochemical activity [8]. An important structural element of the enzyme is
the presence of the “Met20” or “loop 1” consisting of residues 9-24 [17–21]. It helps to stabilize the
nicotinamide ring of NADPH to promote the passage of hydride from NADPH to dihydrofolate and it
is able to open, close or occlude, the active site of the enzyme [22,23]. The amino acid residue Asp27 is
also crucial, because it helps the protonation of the substrate and keeps it in a conformation favorable
to hydride transfer [24]. The structure of the human DHFR in complex with NADPH and with the
antifolate 6-([5-quinolylamino]methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine (PDB ID: 1KMS)
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has been elucidated (Figure 3) [21], thus allowing the foundation for the ad hoc design of compounds
specifically targeting hDHFR.
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Figure 2. Synthetic pathway of f l t etabolism. DHFR catalyzes the passage of a hydride from
the cofactor nicotinamide adenine dinucleotide phosphate (NADPH), used as an electron donor,
to dihydrofolate (DHF), through a protonation to produce tetrahydrofolate (THF). In particular,
DHFR catalyzes the reduction of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate using reduced NADPH as
a cofactor [25]. Therefore, DHFR couples with thymidylate synthase (TS), which catalyzes the reductive
methylation of deoxyuridine monophosphate (dUMP) in deoxythymidine monophosphate (dTMP)
using N5-N10-methylenetetrahydrofolate (5,10-Methylene THF) as a cofactor [26].
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3. Relevance of DHFR Inhibitors in Cancer Therapy
The folate inhibitor methotrexate (Figure 4) was discovered in 1947 by Y. SubbaRow [27]. One year
later, the medical doctor Sidney Farber hypothesized that cancer cells need folate to support their rapid
growth and therefore that methotrexate would slow the progress of cancer. He demonstrated that
methotrexate was effective in reducing symptoms in children with acute lymphoblastic leukemia [24].
A few years later, the drug entered therapy for the treatment of rheumatoid arthritis and psoriasis [28].
To date, methotrexate is widely used in humans for the treatment of some autoimmune diseases and
cancer. Methotrexate is able to inhibit various isoforms of DHFR, and this low selectivity of action
is responsible for the cytotoxicity towards oral mucosa and gastrointestinal (GI) tract epithelial cells,
bone marrow cells, and testicular tissue involved in spermatogenesis [29,30].
Over the past five decades, the several attempts that have been made to obtain more effective
and selective drugs have led to the discovery of the drugs reported in Figure 4 and Table 1 [31–33].
To date, some compounds are in clinical use: raltitrexed, pralatrexate, and pemetrexed, classified as
“classical antifolates”; piritrexim, trimetrexate, talotrexin, and nolatrexed, classified as “non-classical
antifolates”. From a structural point of view, classical antifolates are analogs of folate containing a
pterin ring, an aromatic ring, and a glutamate tail. They do not passively diffuse across cell membranes
because they possess a charged glutamate tail, so they are actively transported through the reduced
folate carrier system [25,34]. Non-classical antifolates are lipophilic molecules which do not need
folate transport systems and passively diffuse into cells. They are able to inhibit tumor cell growth,
so they are useful for the development of new agents against cancer, as well as bacterial and parasitic
infections. The last DHFR inhibitor approved by FDA was pralatrexate in 2009 [35]. It is characterized
by rapid internalization into the cell, a high affinity for dihydrofolate reductase, and a good intracellular
retention (Table 1).
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Table 1. DHFR inhibitors that have been approved [36].
Antifolate Status * Indication Toxicity
Methotrexate Approved by FDA andEMA in 1985
Treatment of lymphoma, acute
lymphoblastic leukemia and
osteosarcoma
Symptoms of overdose include
bone marrow suppression and
gastrointestinal side effects
Raltitrexed Approved by EMA in1998
Treatment of malignant colorectal
cancer, but its utilization in mainly
limited to patients who are
intolerant to 5-fluorouracil
Gastrointestinal and
hematologic side effects
Pemetrexed Approved by FDA andEMA in 2001
First-line treatment for advanced
non-squamous-cell lung cancer
and pleural mesothelioma in
combination with cisplatin
Neutropenia, leukopenia,
anemia, stomatitis and infection
Pralatrexate Approved by FDA andEMA in 2009
Treatment of relapsed or refractory
peripheral T-cell lymphoma (TCL) Mucositis
* Source: DrugBank https://www.drugbank.ca/drugs/DB03695.
4. Inhibitors of Bovine DHFR
To discover new effective DHFR inhibitors, a first screening using bovine DHFR (bDHFR) can be
helpful in the design of drug molecules. Herein, a few examples of prominent bDHFR inhibitors are
provided (Figure 5).
In 2013, Hassan et al., synthesized a new class of DHFR inhibitors based on a
5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiol skeleton and evaluated their in vitro activity
against different cancer cell lines. Among the series, compound 1 is worth mentioning since it is
2.7 times more active than the positive control methotrexate (IC50 = 0.08 µM). Molecular modeling
docking studies with hDHFR (PDB ID: 3EIG) highlighted the amino acids Leu4 and Val1 as essential
for the DHFR binding and the DHFR inhibition activity [37]. In line with these efforts, Ewida et al.
studied in silico the interaction of a compound with a thiazole scaffold with an hDHFR pocket (PDB
ID: 1U70). Through a detailed structural analysis, they pointed out that the thiourea moiety may act
as an anchoring group, helping the thiazole scaffold to fit into the pocket with the right orientation
and position. Starting from these results, the same authors designed and synthetized a new series of
2,4-substituted-1,3-thiazoles and thiazolo[4,5-d]pyridazine. Among all compounds tested, compound
2 (Figure 5) showed the best DHFR inhibition activity, with an IC50 of 0.06 µM. The high binding
affinity of 2 is probably due to the additional interaction with the Phe31 and Arg22. This compound
showed interesting in vitro anticancer properties, being particularly effective against the HS578T breast
cancer cell line [38]. Another step of the research consisted of the preparation of a new compound
series, by replacing the thiazole scaffold with imidazo[2′,1′:2,3]thiazolo[4,5-d]pyridazine. As a result,
the potent bovine liver DHFR inhibitor 3 was discovered. This compound resulted in a promising
anticancer candidate against ovarian cancer cell line OVCAR-3 and melanoma cell line MDA-MB-435,
with IC50 values of 0.32 µM and 0.46 µM, respectively [39].
El-Subbagh et al. prepared a new series of benzodiazepines as anticancer, antiviral,
and antimicrobial agents. The authors provided an efficient synthesis of a new series of
tetrahydro-1H-dibenzo[b,e][1,4]diazepine analogs, presenting an α,β-unsaturated imine function.
The new derivatives have been evaluated as inhibitors of bovine liver DHFR and for their
antitumor activity on different cancer cell lines. Particularly, compound 4 (Figure 5) showed a
good DHFR inhibition efficacy (IC50 = 4 nM), and was 20 times more active than the methotrexate.
To rationalize the results, a molecular modelling study has been performed on hDHFR (PDB ID: 1DLS).
Interestingly, the tetrahydroquinazolines derivatives positively affected the ligand-enzyme interaction,
and the dibenzodiazepine ring possesses the pharmacophoric features essential for activity [40].
Recently, Shahenda et al. synthesized a new series of 2,3,6-substituted quinazolin-4(3H)-ones,
discovering compounds 5 (Figure 5) as the most active inhibitors of DHFR (with IC50 =of 0.02 µM.,
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bovine liver DHFR) [41]. Lastly, El-Gazzar et al. discovered compound 6 (Figure 5) with a
2-mercapto-quinazolin-4(3H)-one structure (IC50 =0.01 µM, bovine liver DHFR) [42].Molecules 2019, 24, x FOR PEER REVIEW 7 of 22 
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It is of high interest that several easy-to-use kits based on ELISA or colorimetric assays, s well
as mammalian (usuall bovine) or human DHFR, are now c mmercially available, thus all wing
an easy screening of potential DHFR inhibitors. No less important, DHFR enzymes belonging to
different species are now well-characterized. DHFR obtained from different species (human, bovine,
murine, and E. coli DHFR) shows a high homology degree and the variations are mainly related to the
hydrophobic nature of the binding site of these enzymes [43].
Many recent papers are focused on the design of new compounds of different structure class with
a high affinity toward human DHFR and selectivity over mammalian DHFR.
5. Inhibitors of Human DHFR under Preclinical Investigation
Since 2009, several DHFR inhibitors have reached clinical trials, but failed at different phases
of the experimental study, owing to their high toxicity (Table 2, Figure 4). The scientific community
Molecules 2019, 24, 1140 8 of 19
is working hard to find new effective DHFR inhibitors, as papers and patents published so far have
demonstrated. Over time, several inhibitors have been prepared, thus allowing the development of
relevant SAR considerations. In this section, we will focus on compounds discovered in the period
2013–2018. Their structural features are briefly summarized hereinafter.
Table 2. DHFR inhibitors withdrawn from clinical trials.
Antifolate ClinicalTrials.govRECORD ID * Status Toxicity
Nolatrexed NCT00012324 Phase 3 study in unresectable hepatocellularcarcinoma (HCC) has been completed (2005)
Nausea, vomiting, stomatitis,
erythematous maculopapular rash,
thrombocytopenia and neutropenia
Piritrexim NCT00002914 Phase 2 study in advanced cancer of the urinarytract has been completed (2004)
Leukopenia, thrombocytopenia,
mucositis
Talotrexin
NCT00088023
NCT00112060
NCT00129558
NCT00458744
It has been suspended in phase 1 in the treatment
of solid tumors (2005).
It was withdrawn in phase 1 in the treatment of
brain and central nervous system tumors, and
malignant lymphomas (2008).
It was withdrawn in phase 2 in the treatment of
non-small-cell lung carcinoma (NSCLC) and
leukemia (2011)
Neurotoxic effect such as fatigue
and hypoxia. At higher and
cumulative doses, it may produce
fatal leukoencephalopathy
* Source: https://clinicaltrials.gov/.
Quinazolines and quinazolinones. Sahu et al. designed in silico (hDHFR, PDB ID: 1S3V) a wide
series of quinazolines and quinazolinones derivatives, structurally related to raltitrexed (Figure 4).
Compound 7 resulted in the most effective ligand of the quinazolinic series (Figure 6) and constituted
the template for the synthesis of the quinazolinone Schiff base in the complex with different metal
ions. Of note, metal-based drugs have been recognized as potential anticancer agents, since they
are characterized by a low toxicity. The authors demonstrated that copper(II) derivatives are active
as antagonists of hDHFR: compound 8 (Figure 6) showed an activity comparable to methotrexate
towards a panel of cancer cell lines [A549 (lungs), SK-OV-3 (ovary), HCT15 (colon), K562 (leukemia),
HeLa (cervix), KB (nasopharyngea), MCF7 (breast) and DU145 (prostate)] [44,45].
In 2013, Al-Omary et al. synthesized a series of 2-heteroarylthio-6-substituted-quinazolin-4-one
analogues. In general, the compounds showed good IC50 values (ranging from 0.3 to 1.0 µM)
on a panel of thirty-one cancer cell lines of leukemia; non-small cell lung cancer; CNS cancer;
melanoma; and ovarian, renal, prostate, and breast cancer. Of particular interest was compound
9, a 2-pyridinylthio-6-substituted-quinazolin-4-one derivative, which was active against different
cancer cell lines [46]. Among the quinazolinones, 2-(1,3,4-thiadiazolyl- or 4-methyl-thiazolyl)thio-
6-substituted-quinazolin-4-ones, prepared by Al-Rashood et al., deserve to be mentioned. Compound
10 (Figure 6) was the most active DHFR inhibitor. The SAR revealed that the substituent at positions
2, 3, and 6 in the quinazolinone nucleus contributes to the DHFR inhibition. Molecular docking
studies explained the molecular bases of DHFR inhibitory activity. Docking studies (the complex
hDHFR-NADPH-methotrexate was used, PDB ID: 1DLS) revealed that the amino acids Glu30, Phe31,
and Phe34 are crucial for the binding interaction with the synthesized compounds. Moreover, in silico
ADMET prediction studies suggested that compound 10 could be used as oral absorbing agents with a
reduced toxicity [34]. In the same year, Chen et al. prepared a new series of pyrrolo[3,2-f ]quinazoline,
and all compounds were tested for their anti-breast cancer activity. Compound 11 (Figure 6) is the
most interesting of the whole series, showing good activity against breast cell lines (MDA-MB-231
GI50 = 1.60 µM; MDA-MB-468 GI50 = 0.44 µM). Surprisingly, it was not able to inhibit hDHFR and
therefore it has been supposed that the antiproliferative activity of compound 11 is independent of
DHFR inhibition. This hypothesis was confirmed by molecular modelling studies which evidenced
that the bulky naphthyl group of compound 11 is not well-accommodated in the binding pocket of
hDHFR. In sum, 11 has been identified as a potent breast cancer agent independent of DHFR, and is
not toxic to normal human mammary epithelial cells (HMEC) up to a 5 µM concentration [47].
Molecules 2019, 24, 1140 9 of 19
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were evaluated for their in vitro antiproliferative activity against HL-60, HeLa, and A549 tumor cell 
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Pyrimid nes and pyridopyrimidines. nds are structurally related to trimetrexate
(Figure 7), currently used for the t eatment of Pneumocycstis cariniii pneumon a i immune compromised
patients and to treat several different forms of cancer (colorectal, h ad, neck, nd lung). Based on
the assumption that the pyridopyrimidines erivatives may interact with DHFR, Du and Zhuang
analyzed thirty two selected pyridopyrimidine derivatives, characterized by the general structure 12
(Figure 7), through a predictive method called the artificial neural network (ANN) to explore their
potential as anticancer compounds. The study evidenced that their activity is strictly related to the
nature and position of substituents on the phenyl ring, as well as the molecular charge distribution.
Substituents at the phenyl moiety seem to play a crucial role in the interaction with the enzyme.
Indeed, both substituents in para and ortho positions markedly decrease the binding with DHFR [48].
The results confirmed the relevance of the pyridopyrimidinic scaffold in DHFR inhibition.
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Yang and Jiaji synthetized a new series of 6-substit t - , - ia inopyrido-[3,2-d]pyrimidine
derivatives (Figure 8) as potential non-classi t ents targeting DHFR. The compounds
were evaluated for their in vitro antiproliferati i st L-60, HeLa, and A549 tumor cell
lines and for the inhibit on of recombinant (r FR). In this series, compounds 13
and 14 stand out above the others for their activit s i i itors, with IC50 values of 0.59 and
0.46 µmol/L, respectively [49]. . ang et al. reported a new series of 2-diamino-6 substituted
pyrido[3,2-d]-pyrimidine derivatives and evaluated their antiproliferative activity against HL-60,
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HeLa, A549, and H1299 human cancer cell lines. In general, the compounds exhibited micromolar
antiproliferative potencies, with the exception of compound 15, which emerged as the most potent
rhDHFR inhibitor, with an IC50 value of 0.06 µM, and displayed interesting anticancer activity against
the HL-60 cell line by inducing DNA damage due to activation of the G1/M checkpoint and the
arrest in S phase [25]. In 2018, Li et al. designed and synthesized a new series of 6-substituted
pyrido[3,2-d]pyrimidines with a three-to-five-carbon bridge. Compound 16, belonging to the three
carbon bridge series, resulted in the most potent rhDHFR inhibitor (IC50 = 0.06 µM), as the molecular
modelling studies on human DHFR (PDB ID: 1U72) confirmed. The antiproliferative activity on three
different human cancer cell lines (HL-60, HCT116, and HeLa) was then evaluated, confirming 16 as
the most active compound. The authors hypothesized that its anti-proliferative activity is due to an
induction of HL-60 cells apoptosis, which led to DNA damage [50].
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Rapolu et al. studied the DHFR inhibitory effect and the anticancer properties of novel substituted
2H-pyrido[1,2-a]pyrimidin-2-ones. Among these, compound 17 (Figure 8) emerged as the most potent
inhibitor, displaying submicromolar inhibition against DHFR (IC50 3.1µM) and a good cytotoxicity
(IC50 lower than 10 µM) against MCF-7 and SK-n-SK [51]. The series of 6-substituted pyrimidine
synthesized by Gangjeeet al. should also be mentioned, since compound 18 not closely related to the
other DHFR drugs appears to be a promising DHFR inhibitors candidate [52].
Triazines. As stated before, DHFR inhibitors commonly used in clinical oncology are characterized
by the presence of both a nitrogen-heterocycle and an additional aromatic moiety, usually a substituted
benzene ring. Starting from this observation and with the aim of introducing an element of structure
novelty, Xiao-Tian Zhou et al. performed a rational drug design of novel hDHFR inhibitors and
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synthesized a series of compounds presenting a dihydro-1,3,5-triazine nucleus and a spirocyclic
heterocycle. They analyzed the interactions of the planar bicyclic ring of hDHFR inhibitors with the
residues in the hDHFR active site (PDB ID: 1U72, 1DLS, 1KMS, 1OHK, 1S3U, 2W3B, 3NTZ). The study
revealed that the presence of the spiro-ring promotes the interaction with the active site of hDHFR,
thanks to a shift of the flexible residue Phe31 in the DHFR pocket. The in vitro biological results
demonstrated that compound 19 (Figure 9) exhibited anti-proliferative activity against tumor cell lines
(HCT116, A549, HL-60, HepG2, and MDA-MB-231), with IC50 in the range of 3.72 nM [53].
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Other compounds. In 2015, Al-Harbi and Bashandy synthetized a wide variety of compounds,
all bearing a substituted benzenesulfonamide portion. The compounds showed high antitumor
activity against the HepG2 hepatocellular carcinoma cell line (mainly compound 20, Figure 10),
with interesting IC50 (1.38-39.70 µg/mL) and selectivity index (SI) (2.06–70.92) values when compared
with methotrexate as a positive control (IC50 = 3.21 µg/mL, SI = 13.30). Molecular docking studies
evidenced that some compounds exhibit strong interactions with the DHFR pocket (PDB ID: 4DFR) [54].
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orga ic synthesis. Despite the advances in this research field, the number of compounds that medicinal
chemists can synthesize is still limited and experimental synthesis is still considered the bottleneck in
the discovery of novel bioactive compounds [56]. From this perspective, nature is a limitless source of
compounds with unique chemical skeletons and potent bioactivities. Nevertheless, o ly a few human
DHFR inhibitors have been isolated from nature, and in particular, from arine and vegetal sources.
Regarding marine sources, interesting compounds have been extracted from sponges. Among these,
bastadin (22, Figure 11), a etabolite of Ircinia muscarum able to inhibit hDHFR with an IC50 value of
2.5 µg/mL, and Puupeheno e (23) and 21-chloro Puupeheno e (24) isolated from a Verongid sponge,
have s own good DHFR inhibitory activity (IC50 = 5 µg/mL) [57].
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Among the novel DHFR inhibitors from the plant kingdom, recently, Kalogris et al. identified
Sanguinarine (25), a natural benzophenanthridine alkaloid derived from the root of Sanguinaria
canadensis, as a potent inhibitor of DHFR, able to induce a modest and significant impairment of
DHFR enzymatic activity [58]. Sanguinarine showed a remarkable anti-neoplastic activity by inducing
apoptosis in various human cancer cell lines, including human breast cancer ones. The authors
demonstrated that the anticancer activity of sanguinarine is DHFR-mediated. The inhibitory effect
on this crucial target has been demonstrated in A17 cells and in MTX-resistant MDA-MB-231 cells,
where the alkaloid reduced the enzyme activity to 30% and 50%, respectively. Notwithstanding,
sanguinarine seems to be capable of reducing the enzyme activity also in the BLBC cells, resistant
to MTX.
Within a wider research project aimed at discovering the antitumor and antifolate activity of a
series of popular medicinal plants, Albalawi et al. identified Caralluma sinaica and Fagonia tenuifolia as
potential anticancer-drug sources worthy of further investigation. The best results in terms of in vitro
inhibition of DHFR activity were shown by Sonchus oleraceus extracts (0.06 µg/L) and Caralluma
sinaica extracts (0.10 µg/L). Since Caralluma sinaica extracts are active in both antitumor and antifolate
assays, they could assume that the anticancer activity of this plant proceeds through DHFR inhibition.
Thus, this study provides scientific support for the use of Caralluma sinaica as a medicinal anticancer
plant [59].
Lastly, also curcumin, which therapeutic potential against several diseases, including cancer,
has been identified as being able to prominently bind molecules of the DHFR enzyme by Yahya
et al. In detail, they predicted the interaction of curcumin by molecular docking on the DHFR
active site (PDB ID: 1DRE). Surprisingly, the analysis revealed that curcumin binds to DHFR with a
strong affinity, even comparable to that of methotrexate, as confirmed by the values of free binding
energy (∆G = −9.02 kcal/mol; Ki = 243 nM for curcumin and ∆G = −8.78 kcal/mol; Ki = 363 nM for
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methotrexate). These results suggest that curcumin may interact with the enzyme with similar modes
of action of known DHFR inhibitors. Furthermore, curcumin (26) is able to optimize the interactions on
both sides of the enzyme pocket because it binds to a folded conformation in the active site of DHFR
due to its structural flexibility. It also establishes van der Waals interactions with some active enzyme
residues and a pi-pi interaction with the phenyl ring of Phe34 and the phenyl ring of curcumin, in the
active site pocket. Further studies are necessary for confirming this mechanism of action [60].
As highlighted in the previous paragraphs, different research groups are involved in the
design and synthesis of novel DHFR inhibitors as effective drugs for counteracting cancer. In vitro
biological properties and corresponding SAR of investigated compounds clearly correlate the DHFR
inhibition with the anticancer effect. Several scaffolds have been identified, opening the door for
the development of better drugs. As previously outlined, most SAR studies suggest that at least
the presence of a heterocyclic cycle is necessary for an anticancer effect, with the only exception of
sulfonamide derivatives.
6. New Strategies in DHFR Drug Discovery
It is well-known that the use of drugs in combination, compared to the mono-therapy approach,
may have synergistic or additive efficacy against cancer. Accordingly, hybrid compounds are a
good strategy for cancer treatment. Arooj et al. discovered potential dual inhibitors of human
thymidylate synthase (hTS) and hDHFR, by developing a pharmacophoric model with the chemical
features necessary for the dual inhibition of target enzymes (hDHFR, PDB ID: 1U72; hTS, PDB ID:
1HVY). Afterwards, they applied a virtual screening approach, starting from a drug-like database.
Once compounds with different scaffolds potentially able to interact with both targets have been
selected, optimization studies have been performed, leading to dual compounds with excellent binding
characteristics towards the target proteins (compound 27, Figure 12) [61].
In 2017, Tian et al prepared a new series of 6-substituted pyrrolo[3,2-d]pyrimidines acting as
dual inhibitors on TS and DHFR. Molecular modelling studies demonstrated that all synthetized
compounds interact on the active sites of hTS (PDB ID: 1JU6) and hDHFR (PDB ID 1U72) enzymes with
high binding affinity values. The enzyme assay on DHFR established that the most active compound
was 28 (Figure 12), with an inhibitory ratio of 66.7% at 100 µM. Among all synthesized compounds,
only 28 showed a good anti-proliferative activity against A549, NCI-H1299, and HL60 tumor cell lines,
with GI50 values of 0.73, 1.72, and 8.92 µM, respectively. Moreover, 28 has determined G2/M phase
arrest on cell cycle distribution in A549 cells [62].
Shaveta and Singh synthesized a series of indole, pyrazole, and barbituric acid conjugates as
potential anticancer agents. Of particular interest is compound 29 (Figure 12), which is active against
non-small cell lung cancer NCI-H522. This compound interacts with enzymes involved in the cancer
diffusion process like DHFR, RNR (ribonucleotide reductase), TS, and TP (thymidylate phosphorylase).
Molecular docking studies on the hDHFR pocket (PDB ID: 3GHW) revealed that compound 29
established H-bonds between pyrazolic nitrogen and the Gln35 residue of the α-helix of the enzyme,
so it was placed in the active site of the enzyme. Moreover, the indole moiety established a favorable
hydrophobic interaction, while the p-chlorobenzoyl group established a polar interaction. These results
showed that the indole moiety aligns parallel with the β sheet, while the p-chlorobenzoyl fragment
overlaps with the other β-sheet, revealing the compatibility of compound 29 towards the active site of
DHFR [63].
In 2016, Singla et al. synthesized a new series of triazine-benzimidazole analogues with a
4-fluoroaniline moiety. The in vitro effect of all compounds on human cancer cell lines has been
evaluated and DNA intercalation studies performed. All compounds exhibited intercalation properties
with ct-DNA (calf thymus-DNA) and they also exerted significant DHFR inhibitory activity, with IC50
values ranging from 0.11 to 42.4 µM. SAR studies revealed that the nature of the substituent in the C2-
and C6- positions of triazine nucleus influences the activity, and among all, compound 30 turned out
to be the most active hDHFR inhibitor, with an IC50 value of 2.0 nM [64].
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In the same year, Ng et al. evaluated the effect of the co-administration of dihydrotriazine
acting as DHFR inhibitors and chalcones acting as thioredoxin reductases (TrxR) inhibitors for the
treatment of breast (MCF-7) and colorectal (HCT116) carcinoma cells. The co bination therapy
showed a synergic anti-proliferative effect. Starting from these results, the authors synthesized four
dihydrotriazine-chalcone hybrid compounds. Among these, compound 31 [DHFR IC50 = 2.4 µM,
TrxR IC50 (60 min) = 10.1 µM] demonstrated in vitro inhibition of both DHFR and TrxR (Figure 12) [65].
The same authors synthesized fifteen new compounds, connecting the two scaffolds through a diether
linker (Figur 12), su cessfully obtaining dual inhibit rs against DHFR and TrxR, as demonstrated by
in vitro enzyme assays with IC50 values ranging from 2.6–53.4 nM on DHFR and IC50 values ranging
from 3.8–32.4 µM on TrxR. All compounds showed cytotoxic activity against HCT116 and MCF-7
cancer cell lines (methotrexate sensitive), exhibiting a biphasic dose-response c rve. GI50 range values
were from 0.011 to 2.18 µM and LC50 ra ge v lues w re from 9.7 to 81.9 µM. It is w rth noting that the
length of the diether linker influenced the growth inhibitory effects: compound 32 with a linker length
of three carbon atoms showed the strongest growth inhibitory activities (GI50 of 0.026 µM on HCT116
cells andGI50 of 0.008 µM on MCF-7 cells) [66].
Lastly, Hsieh et al. proposed a novel mechanism to induce DHFR degradation through cofactor
depletion in neoplastic cells by the inhibition of NAD kinase. The authors identified an inhibitor
of NAD kinase, thionicotinamide adenine dinucleotide phosphate (NADPS), which accelerated the
degradation of DHFR and inhibited cancer cell growth. They demonstrated that the combination
treatment of NADPS with methotrexate displayed a synergic effect in metastatic colon cancer cell lines
and proposed NAD kinase as a valid target for further inhibitor development for cancer treatment [67].
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7. Conclusions
The role of the DHFR enzyme as a therapeutic target in cancer treatment has been well-recognized
for several years and the discovery of new compounds able to inhibit this enzyme continues to attract
the interest of medicinal chemists. The analysis of the scientific literature of the last six years showed
that all novel DHFR inhibitors (both synthetically or naturally derived) are characterized by the
presence of heterocyclic moieties in the structure, with the only exception of sulphonamides. Lastly,
dual compounds, combining DHFR with other folate receptors (FRs) inhibition and endowed with
interesting antitumor properties, have recently been discovered. In this scenario, multi-target drugs are
a promising approach for discovering anti-cancer agents. A new generation of DHFR inhibitors able to
simultaneously bind different targets may be designed, which could lead to novel effective drugs.
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Abbreviations
FA Folic acid
THF tetrahydrofolate
DHFR dihydrofolate reductase enzyme
hDHFR human DHFR
bDHFR bovine DHFR
rhDHFR recombinant human DHFR
hTS human thymidylate synthase
NADPH nicotinamide adenine dinucleotide phosphate
dUMP dihydrofolate synthase (DHFS), deoxyuridine monophosphate
dTMP deoxythymidine monophosphate
5,10-Methylene THF N5-N10-methylenetetrahydrofolate
TrxR thioredoxin reductases
FRs folate receptors
ct-DNA calf thymus-DNA
RNR ribonucleotide reductase
TS thymidylate synthase
TP thymidylated phosphorylase
MTX methotrexate
ANN artificial neural network
PDB Protein Data Bank
Asp127 Aspartate 127
Glu30 Glutamate 30
Phe31 Phenylalanine
ELISA assay enzyme-linked immunosorbent assay
FDA U.S. Food and Drug Administration
EMA European Medicines Agency
ADMET absorption, distribution, metabolism, excretion, toxicity
OVCAR-3 ovarian cancer cell line
MDA-MB-435 melanoma cell line
NSCLC non-small-cell lung carcinoma
HCC hepatocellular carcinoma
A549 adenocarcinomic human alveolar basal epithelial cells
SK-OV-3 human ovary cancer cell line
HCT15; HCT116 human colon adenocarcinoma colorectal adenocarcinoma
K562 human chronic myeloid leukemia cell
HeLa human of immortal cervical cancer cell
KB keratin-forming tumor cell line HeLa
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MCF-7; MDA-MB-231; MDA-MB-468 human breast cancer cell line
DU145 human prostate cancer cell line
HMEC normal human mammary epithelial cells
HL-60 human caucasian promyelocytic leukemia cell line
NCI-H1299; NCI-H522 human non-small cell lung carcinoma cell line
HepG2 human liver cancer cell line
SK-n-SH human neuroblastoma
A17 amacrine cells in mammalian retina
SAR structure activity relationships
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